OXBR vs. NEUE, AAME, ZBAO, HUIZ, FGF, AIFU, CNFR, TIRX, XHG, and ACGLO
Should you be buying Oxbridge Re stock or one of its competitors? The main competitors of Oxbridge Re include NeueHealth (NEUE), Atlantic American (AAME), Zhibao Technology (ZBAO), Huize (HUIZ), Fundamental Global (FGF), AIFU (AIFU), Conifer (CNFR), Tian Ruixiang (TIRX), XChange TEC.INC. (XHG), and Arch Capital Group (ACGLO). These companies are all part of the "insurance" industry.
Oxbridge Re vs. Its Competitors
NeueHealth (NYSE:NEUE) and Oxbridge Re (NASDAQ:OXBR) are both small-cap insurance companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.
In the previous week, Oxbridge Re had 2 more articles in the media than NeueHealth. MarketBeat recorded 3 mentions for Oxbridge Re and 1 mentions for NeueHealth. NeueHealth's average media sentiment score of 0.00 beat Oxbridge Re's score of -0.04 indicating that NeueHealth is being referred to more favorably in the media.
NeueHealth presently has a consensus target price of $7.00, indicating a potential upside of 3.09%. Oxbridge Re has a consensus target price of $5.00, indicating a potential upside of 145.10%. Given Oxbridge Re's stronger consensus rating and higher probable upside, analysts plainly believe Oxbridge Re is more favorable than NeueHealth.
NeueHealth has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Oxbridge Re has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500.
Oxbridge Re has lower revenue, but higher earnings than NeueHealth. Oxbridge Re is trading at a lower price-to-earnings ratio than NeueHealth, indicating that it is currently the more affordable of the two stocks.
63.9% of NeueHealth shares are held by institutional investors. Comparatively, 5.6% of Oxbridge Re shares are held by institutional investors. 63.3% of NeueHealth shares are held by company insiders. Comparatively, 19.5% of Oxbridge Re shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
NeueHealth has a net margin of -14.28% compared to Oxbridge Re's net margin of -143.80%. NeueHealth's return on equity of 0.00% beat Oxbridge Re's return on equity.
Summary
NeueHealth and Oxbridge Re tied by winning 8 of the 16 factors compared between the two stocks.
Get Oxbridge Re News Delivered to You Automatically
Sign up to receive the latest news and ratings for OXBR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OXBR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Oxbridge Re Competitors List
Related Companies and Tools
This page (NASDAQ:OXBR) was last updated on 7/26/2025 by MarketBeat.com Staff